Literature DB >> 30826602

Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection.

Arnaud Chalin1, Benjamin Lefevre2, Christelle Devisme3, Nathalie Barget4, Laurence Amiot2, Michel Samson5.   

Abstract

BACKGROUND & AIMS: The chemokines CXCL10 (interferon ϒ-inducible protein 10 [IP-10]), CXCL11 (Human interferon inducible T cell alpha chemokine [I-TAC]), and CXCL12 (stromal cell derived factor 1 [SDF-1]) contribute to cell recruitment, migration, activation, and homing in liver diseases and their serum levels have been shown to be associated with the degree of liver inflammation or fibrosis in various etiologies. However, the data may be contradictory or insufficient, particularly for CXCL12, in the field of chronic HCV infection. Here, we aimed to provide evidence for these chemokines as biomarkers for chronic HCV infection.
METHODS: We analyzed the serum concentration of the three chemokines in healthy donors (n = 39) and patients (n = 87) with chronic HCV infection. Chemokine serum levels were compared to the stage of liver inflammation and fibrosis obtained from liver biopsies.
RESULTS: Serum CXCL10 and CXCL11 levels were higher at advanced stages of liver inflammation than at earlier stages, but the results were only of medium significance. Both serum CXCL11 and CXCL12 levels were significantly higher in cirrhotic patients than those with low or medium stages of fibrosis. The AUROCs were 0.8167 and 0.8574, respectively, for the diagnosis of cirrhotic patients.
CONCLUSION: These data provide evidence for the value of CXCL10, CXCL11, and CXCL12 as biomarkers of liver inflammation and fibrosis during chronic HCV infection. Serum CXCL10 and CXCL11 levels were associated with liver inflammation, but the level of significance was insufficient. However, serum CXCL11 and CXCL12 levels were elevated in cirrhotic patients, showing equivalent diagnostic accuracy as the existing established single serum fibrosis markers or algorithms.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  CXCL10; CXCL11; CXCL12; Chronical HCV infection; Fibrosis

Mesh:

Substances:

Year:  2019        PMID: 30826602     DOI: 10.1016/j.cyto.2019.02.006

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

1.  Bioinformatics analyses of significant genes, related pathways, and candidate diagnostic biomarkers and molecular targets in SARS-CoV-2/COVID-19.

Authors:  Basavaraj Vastrad; Chanabasayya Vastrad; Anandkumar Tengli
Journal:  Gene Rep       Date:  2020-11-04

2.  Colon cancer cells secreted CXCL11 via RBP-Jκ to facilitated tumour-associated macrophage-induced cancer metastasis.

Authors:  Mengjie Liu; Xiao Fu; Lili Jiang; Jiequn Ma; Xiaoqiang Zheng; Shuhong Wang; Hui Guo; Tao Tian; Kejun Nan; Wenjuan Wang
Journal:  J Cell Mol Med       Date:  2021-10-16       Impact factor: 5.310

Review 3.  The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.

Authors:  Eva M García-Cuesta; César A Santiago; Jesús Vallejo-Díaz; Yasmina Juarranz; José Miguel Rodríguez-Frade; Mario Mellado
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-27       Impact factor: 5.555

4.  Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus.

Authors:  Aya Ishizaka; Michiko Koga; Taketoshi Mizutani; Lay Ahyoung Lim; Eisuke Adachi; Kazuhiko Ikeuchi; Ryuta Ueda; Haruyo Aoyagi; Satoshi Tanaka; Hiroshi Kiyono; Tetsuro Matano; Hideki Aizaki; Sachiyo Yoshio; Eiji Mita; Masamichi Muramatsu; Tatsuya Kanto; Takeya Tsutsumi; Hiroshi Yotsuyanagi
Journal:  Viruses       Date:  2021-10-18       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.